Google
Trusted Resources: News & Events
Latest announcements and gatherings
Spectra Optia Device Save Way to Treat Sickle Cell While Using Less Blood Cell Packs, Study Finds
The blood-separation device Spectra Optia, which has the ability to remove abnormal red blood cells from sickle cell patients, can efficiently and safely replace these cells with healthy red blood cells from donors, a study reports.
The therapeutic tool also uses less red blood cell units than regular transfusion techniques, i.e., without the removal of abnormal red blood cells (RBCs).
The study, “Automatic depletion with Spectra Optia allows a safe 16% reduction of red blood cell pack consumption in exchanged sickle cell anemia patients,” was published in the journal Transfusion.
Sickle-cell anemia results from an abnormality in the oxygen-carrying protein hemoglobin found in red blood cells. Cells become sticky and rigid, with a sickle or crescent moon shape, and are prone to getting trapped in small vessels, stopping the blood from circulating and causing painful vaso-occlusive crisis.
+myBinderRelated Content
-
Novo Nordisk obtains licence for sickle cell disease programNovo Nordisk inked a global licence deal...
-
A single center experience of GBT440 treatment of severe anemia in sickle cell diseaseBackground: GBT440 is an oral, once-dail...
-
Inhaled steroids reduce pain and sVCAM levels in individuals with sickle cell disease: A triple-blind, randomized tr...Clinical and preclinical data demonstrat...
-
FDA grants CRISPR gene therapy fast track designation for sickle cell diseaseThe FDA granted fast track designation t...
-
Phase 3 Trial of Rivipansel in Treating SCD Pain Crisis Fails to Meet Goals, Pfizer AnnouncesThe Phase 3 RESET trial testing the effe...
-
‘Natural’ Gene Mutation May Offer Way of Treating Sickle Cell Disease, Study SaysIntroducing a “natural” genetic muta...
-
First systemic evidence for safety of tPA in stroke patients with sickle cell diseaseIn the largest report on acute stroke in...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.